Bausch Health stock closed CAD 8.92 on October 16, 2026, 19.50 percent below high

Published on 10/17/2026 at 21:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 2.83 billion on July 29, 2026. Bausch Health stock closed at CAD 8.92 on October 16, 2026, down 0.67 percent versus CAD 8.98.

Range and valuation context

The latest 52-week range extended from CAD 6.10 to CAD 11.08 as of October 16, 2026.
Second-quarter revenue reached USD 2.83 billion against USD 2.59 billion expected on July 29, 2026.
Bausch Health stock closed at CAD 8.92 on October 16, 2026 at 4:00 p.m. ET, down 0.67 percent versus the prior close of CAD 8.98.
Market capitalization stood at CAD 3.3 billion and the P/E ratio was minus 2.14 as of October 16, 2026.

BHC, CA0717341071, Illustration mit AI erstellt.

Bausch Health stock stood 19.50 percent below its 52-week high of CAD 11.08 in the latest quoted session. The price closed at CAD 8.92 on October 16, 2026 at 4:00 p.m. ET, down 0.67 percent versus the prior close of CAD 8.98.

Second-quarter results beat estimates

The company’s latest reported quarter remains the clearest operating reference for the valuation. MarketBeat reported that second-quarter revenue reached USD 2.83 billion against analyst expectations of USD 2.59 billion on July 29, 2026. Earnings per share came to USD 1.26 versus a USD 0.96 consensus estimate for the same quarter.

The comparison matters because Bausch Health is still valued against a weak earnings base. The finance profile shows a market capitalization of CAD 3.3 billion and a negative P/E ratio of minus 2.14 as of October 16, 2026. The company operates across specialty pharmaceuticals, eye health, gastroenterology and dermatology.

Range leaves room below high

The latest 52-week range ran from CAD 6.10 to CAD 11.08. At CAD 8.92, the stock was 46.23 percent above its low and 19.50 percent below its high. Trading volume was 380,837 shares against an average of 680,998 shares in the quoted session.

Valuation and October date

The next scheduled corporate date is October 28, 2026, when Bausch Health is due to report third-quarter results. The company’s investor-relations calendar also lists the presentation for 5:00 p.m. EDT. Bausch Health said on October 12, 2026 that preliminary third-quarter results supported an expected increase in full-year 2026 adjusted earnings before interest, taxes, depreciation and amortization guidance.

Comparison with peers

Bausch Health: minus 0.67 percent, P/E minus 2.14, market capitalization CAD 3.3 billion.
Takeda (NYSE, USD): plus 1.13 percent, P/E 55.47, market capitalization USD 62.6 billion.
Teva (NYSE, USD): plus 0.95 percent, P/E 68.97, market capitalization USD 48.4 billion.

Price remains below yearly high

The closing level places Bausch Health materially below its yearly high while remaining above the quoted low. The October 28 reporting date is the next firm calendar marker for investors assessing whether the operating improvement described for the second quarter continues.

Bausch Health stock closed at CAD 8.92 on October 16, 2026 at 4:00 p.m. ET, down 0.67 percent versus the prior close of CAD 8.98.